Trial Profile

A Phase 1, Open-Label, 4-Part Study to Evaluate the Effect of Food, Cytochrome P 450 Inhibition and Induction on the Pharmacokinetics of CC 122 in Healthy Adult Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avadomide (Primary) ; Fluvoxamine; Itraconazole; Rifampicin
Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Glioblastoma; Liver cancer; Malignant melanoma; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
Focus Pharmacokinetics
Sponsors Celgene Corporation

Most Recent Events

06 Jun 2019 Results assessing drug-drug interaction to study effect of cytochrome P450 inhibition and induction on the pharmacokinetics of the Avadomide in healthy adult subjects published in the Journal of Clinical Pharmacology
28 Feb 2018 Status changed from not yet recruiting to completed.
16 Nov 2017 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com